Followers | 0 |
Posts | 2177 |
Boards Moderated | 0 |
Alias Born | 04/13/2018 |
Friday, May 07, 2021 1:23:10 PM
So we have that. Now let's review the drug itself.
1. Receptor Occupancy is at issue.
2. 700mg data which we supposedly have has mysteriously not been filed.
3. No trial to date has successfully shown that the drug actually works or should be approved.
But let's dig deeper into the company's playbook when it comes to accomplishing goals and seeking revenue.
1. Anytime a project nears completion or requires a formal approval. CYDY switches to another project further back of any other.
2. HIV the closest to any study in terms of approval and generating revenue has no timeline assigned and no further substantive updates from management. Literally the life line of the company is no where insight.
3. The COVID studies have all failed, and require new trials per Nader. These trials however are now being conducted mostly outside of the United States away from the eyes of a major regulatory agency.
4. Nader and CYDY is attempting to contravene international law by trying to charge a fee for compassionate use. They are trying to get away with avoiding the laws regarding the commercial sales of unapproved drugs. So you will have a US company selling an unapproved drug.
The last time any compassionate use drug was allowed to "charge a fee" was medical cannibus but that was through a special act of their congress:
https://www.congress.gov.ph/legisdocs/third_17/HBT6517.pdf
So again a case of Nader not doing his homework or outright lying. A simple Google search would have informed him that the regulatory issues surrounding this would require more than a phone call to their FDA.
Why do I think Nader is lying and knows better. Because he is tossing maybes around like M&Ms. The same kind of stock pumping statements like the forever infamous "conditional EUA." His backtracking on that on the last Conference Call should be a dead giveaway on how he came up with "It's not commercial sales, it's a fee." Think of him explaining that before prosecutors, congress or a major regulatory body.
Nader has to go he is taking the company into legally perilous waters and putting off revenue producing projects. The man is a menace.
Recent CYDY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:48:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:47:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:47:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:46:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:45:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 01:45:06 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/17/2024 09:15:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/15/2024 09:16:35 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/11/2024 01:00:15 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/01/2024 09:15:42 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 09/30/2024 09:01:16 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/13/2024 04:15:06 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/07/2024 12:44:56 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/07/2024 12:42:22 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/15/2024 09:21:30 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/22/2024 01:00:58 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:17:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:16:28 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/09/2024 09:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 12:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM